PHA-022484

PHA-022484 is a potent and selective small molecule inhibitor of the enzyme 11β-hydroxysteroid dehydrogenase type 1 (11β-HSD1). This enzyme plays a critical role in glucocorticoid metabolism by converting inactive cortisone into active cortisol, primarily within the liver, adipose tissue, and skeletal muscle. By blocking this conversion, PHA-022484 aims to lower local cortisol concentrations, which is hypothesized to improve insulin sensitivity, reduce hepatic glucose production, and mitigate the metabolic consequences of obesity and type 2 diabetes. Developed by Pharmacia (subsequently Pfizer), the compound was part of a broader effort to target the 11β-HSD1 pathway for metabolic syndrome, though development did not proceed to late-stage clinical trials.